How Trial Participation Is Becoming Easier: Decentralization
Clinical trial participation can be difficult if you need to travel, find child or elder care, or require financial assistance. In the first of a two-part series,...
Read MoreFDA Expands Approval for Enhertu®
On May 5, 2022, the FDA expanded approval for trastuzumab deruxtecan (Enhertu®, AstraZeneca and Daiichi Sankyo) for the treatment of patients with HER2-positive...
Read MoreTriple-Negative Metastatic Breast Cancer: Beyond ER, PR, and HER2
Triple-negative breast cancer is defined as being negative for the estrogen receptor, progesterone receptor, and HER2 biomarkers. Because of this, targeted...
Read MoreBreast Cancer Brain Metastasis: Highlighting the Experts
Many doctors specialize in treating breast cancer that has spread to the brain (brain metastasis). Visit the links below for a panel discussion with MBC brain...
Read MorePatient Advocate Foundation, Our Newest Partner!
Our newest Metastatic Trial Search partner is Patient Advocate Foundation (PAF). PAF helps guide patients and their families through complex healthcare challenges...
Read MoreWhy Attend a Medical Conference?
Patients attend medical conferences to network with other patients, learn about cutting-edge research, and participate in ways that allow the patient voice to be...
Read MoreAll About Phase IV Clinical Trials
In the last 3 months, we highlighted what to know about phase I, phase II, and phase III clinical trials. In the last of our four-part series, we are discussing...
Read MoreUpdate on Immunotherapy for MBC: Immune Checkpoint Inhibitors
Immune checkpoint inhibitors are a type of immunotherapy that uses the immune system’s natural ability to fight cancer. Immunotherapy is an active area of...
Read MoreWhy Do Some People Have an Exceptional Response When Being Treated for MBC?
Exceptional responders, also called atypical responders, are people with cancer who have responded to treatments that are not as effective for other people. Many...
Read MoreSEARCH OUR SITE
for past articles or specific information.